NeOnc's NEO100 Therapy Significantly Increases Survival Rates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Globenewswire
- Clinical Results Update: NeOnc Technologies reports that its NEO100 therapy achieved a significant radiographic remission rate of 24% in 25 patients, which is a 300% increase over the typical 8% seen with salvage therapies, indicating strong efficacy and competitive potential in the market.
- Survival Rate Improvement: Among patients treated with NEO100, 36% remained alive 18 months post-treatment, suggesting that this therapy may provide durable survival benefits in heavily pretreated populations, thereby altering treatment strategies.
- No Significant Toxicity: The intranasal administration of NEO100 has shown no significant toxicity even with prolonged use, ensuring patient safety and providing strong support for its clinical application.
- Broad Treatment Prospects: As the dataset expands, NEO100 is emerging as a potential first-in-class CNS-penetrant metabolic therapy, marking a possible paradigm shift in the treatment of IDH1-mutant high-grade gliomas and pushing the industry towards more effective treatment options.
Analyst Views on NTHI
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
